Method for establishing hepatic fibrosis model through hyperhomocysteinemia induction

A technology for cysteinemia and liver fibrosis, which can be applied to pharmaceutical formulations, medical preparations containing active ingredients, organic active ingredients, etc., and can solve problems such as unclear expression of liver fibrosis

CN106577476AActive Publication Date: 2017-04-26唐博
5 Cites 3 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
Publication Date
2017-04-26

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a method for establishing a hepatic fibrosis model through hyperhomocysteinemia induction and belongs to the field of hepatic disease research in medical science. According to the method, hyperhomocysteinemia is established through oral medication of methionine which is conducted at present, so that the mouse hepatic fibrosis model is established through induction; and then, homocysteine in blood is measured, measurement is conducted through a western blot method, masson staining conducted on tissues, and identification is conducted through an immunohistochemical method. The mouse hepatic fibrosis model established through the method is easy to operate, short in cycle and high in success rate. By means of establishment of the fibrosis model, a reliable animal model is provided for deeply researching pathogenesis of fibrosis, preliminarily screening various treatment drugs and the like.
Need to check novelty before this filing date? Find Prior Art

Description

Technical field

[0001] The invention belongs to the field of biotechnology, and specifically relates to a method for establishing a liver fibrosis model induced by hyperhomocysteinemia. Background technique

[0002] Hcy is a sulfur-containing amino acid, an intermediate product of methionine metabolism, and it participates in a key link in the methionine cycle. HCY in the blood rises to a certain level (usually> 16uM) form hyperhomocysteinemia. The clinical manifestations of hyperhomocysteinemia are diverse, including fatty liver and liver fibrosis.

[0003] Liver fibrosis is a serious disease worldwide. It is caused by abnormal proliferation of connective tissue in the liver leading to liver cell damage. Pathological factors include viral hepatitis, alcoholism, immune damage, and extracellular matrix. In the stage of liver cirrhosis, the damage of liver function caused by a large amount of extracellular matrix (ECM) deposition is irreversible. The pathological process of l...

Examples

Embodiment Construction

[0028] Hereinafter, the embodiments of the present invention will be described in detail with examples, so as to fully understand and implement the implementation process of how the present invention uses technical means to solve technical problems and achieve technical effects.

[0029] The present invention provides a method for establishing a liver fibrosis model induced by hyperhomocysteinemia, which comprises the following steps:

[0030] Step 1. Prepare a model of hyperhomocysteinemia induced by high methionine diet in vivo:

[0031] Step 1.1, such as figure 1 As shown, 20 C57BL / 6 mice aged 6-8 weeks were selected and randomly divided into 2 groups, each with 10 mice. One group was fed with normal diet (normal mouse liver tissue), and one group was fed with a percentage of quality 2% high methionine feed (contains enough B vitamins) (modeling), 2 weeks later, the mice were sacrificed, blood was collected from the inferior vena cava, the blood of the mice was collected to test t...